Dynamic Expression Profile of p21WAF1/CIP1 and Ki-67 Predicts Survival in Rectal Carcinoma Treated With Preoperative Radiochemotherapy
- 15 September 2003
- journal article
- gastrointestinal cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (18), 3391-3401
- https://doi.org/10.1200/jco.2003.07.077
Abstract
Purpose: We investigated p53 and its downstream effectors p21WAF1/CIP1, BAX, and hMSH2 as well as the proliferation marker Ki-67 (mki-67/MIB-1) in patients undergoing preoperative radiochemotherapy for rectal carcinoma to identify prognostic and predictive factors. The focus of this study was on the dynamics of these genetic markers in a longitudinal study—that is, before and after radiochemotherapy. Patients and Methods: Expression of p53, BAX, p21WAF1/CIP1, Ki-67, and hMSH2 was investigated by immunohistochemistry in pre- and posttherapeutic tumor samples in 66 patients. Tumor DNA was screened for p53 mutations by single-strand conformation polymorphism–polymerase chain reaction (SSCP-PCR). Paired tumor samples (pretherapy and posttherapy) were collected prospectively. Results: Patients with a decrease in p21 expression following radiochemotherapy had better disease-free survival (P = .03). Similarly, patients with an increase in proliferative activity as measured by increased Ki-67 expression posttherapy had better disease-free survival (P < .005). In addition, we observed a significantly better prognosis for patients with high hMSH2 expression. In contrast, pretherapeutic levels of p53, BAX, or p21 expression and p53 mutation had no prognostic value, indicating that the combination of radiotherapy and chemotherapy might override defects in these genes. Conclusion: These findings are novel and support the clinical relevance of p21 in the suppression of both proliferation and apoptosis. Thus, the dynamic induction of p21WAF1/CIP1 was associated with a lower proliferative activity but an ultimately worse treatment outcome following neoadjuvant radiochemotherapy and tumor resection. Induction of p21, therefore, represents a novel resistance mechanism in rectal cancer undergoing preoperative radiochemotherapy.This publication has 33 references indexed in Scilit:
- Combined p53/Bax mutation results in extremely poor prognosis in gastric carcinoma with low microsatellite instabilityCell Death & Differentiation, 2003
- Analysis of p53/BAX in primary colorectal carcinoma: Low BAX protein expression is a negative prognostic factor in UICC stage III tumorsInternational Journal of Cancer, 2002
- The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell linesOncogene, 2002
- Identification of a p53 Response Element in the Promoter Region of the hMSH2 Gene Required for Expression in A2780 Ovarian Cancer CellsOnline Journal of Public Health Informatics, 2001
- Molecular Predictors of Survival after Adjuvant Chemotherapy for Colon CancerThe New England Journal of Medicine, 2001
- A role for mismatch repair in control of DNA ploidy following DNA damageOncogene, 2001
- Relevance of Ki-67 antigen expression and K- ras mutation in colorectal liver metastasesEuropean Journal of Surgical Oncology, 2001
- Identification of CIP-1-associated Regulator of Cyclin B (CARB), a Novel p21-binding Protein Acting in the G2 Phase of the Cell CycleOnline Journal of Public Health Informatics, 2000
- Twenty years of p53 research: structural and functional aspects of the p53 proteinOncogene, 1999
- Preoperative Hyperthermia Combined with Radiochemotherapy in Locally Advanced Rectal CancerAnnals of Surgery, 1998